JP5461423B2 - 新規風疹ｅ１エンベロープタンパク質変異体および抗風疹抗体の検出におけるその使用 - Google Patents

新規風疹ｅ１エンベロープタンパク質変異体および抗風疹抗体の検出におけるその使用 Download PDF

Info

Publication number
JP5461423B2
JP5461423B2 JP2010537314A JP2010537314A JP5461423B2 JP 5461423 B2 JP5461423 B2 JP 5461423B2 JP 2010537314 A JP2010537314 A JP 2010537314A JP 2010537314 A JP2010537314 A JP 2010537314A JP 5461423 B2 JP5461423 B2 JP 5461423B2
Authority
JP
Japan
Prior art keywords
rubella
antigen
cys
disulfide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010537314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505811A5 (https=
JP2011505811A (ja
Inventor
ショルツ，クリスティアン
ボルハーゲン，ラルフ
エンゲル，アルフレート
ファーツ，エルケ
シャールシュミット，ペーター
ウプマイアー，バルバラ
ツァルント，トラルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2011505811A publication Critical patent/JP2011505811A/ja
Publication of JP2011505811A5 publication Critical patent/JP2011505811A5/ja
Application granted granted Critical
Publication of JP5461423B2 publication Critical patent/JP5461423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/19—Rubella virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2010537314A 2007-12-13 2008-12-11 新規風疹ｅ１エンベロープタンパク質変異体および抗風疹抗体の検出におけるその使用 Active JP5461423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07024190.6 2007-12-13
EP07024190 2007-12-13
PCT/EP2008/010532 WO2009074318A2 (en) 2007-12-13 2008-12-11 Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies

Publications (3)

Publication Number Publication Date
JP2011505811A JP2011505811A (ja) 2011-03-03
JP2011505811A5 JP2011505811A5 (https=) 2011-06-30
JP5461423B2 true JP5461423B2 (ja) 2014-04-02

Family

ID=40671057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537314A Active JP5461423B2 (ja) 2007-12-13 2008-12-11 新規風疹ｅ１エンベロープタンパク質変異体および抗風疹抗体の検出におけるその使用

Country Status (7)

Country Link
US (1) US8551696B2 (https=)
EP (1) EP2222694B1 (https=)
JP (1) JP5461423B2 (https=)
CN (1) CN101939330B (https=)
CA (1) CA2705716C (https=)
ES (1) ES2450998T3 (https=)
WO (1) WO2009074318A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2706115A1 (en) 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays
AR093778A1 (es) 2012-11-08 2015-06-24 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4
BR112016025056A2 (pt) 2014-05-14 2018-02-20 F. Hoffmann-La Roche Ag uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
JP2018527395A (ja) * 2015-09-30 2018-09-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 改良モジュール型抗原移送分子及び動物におけるその使用
JP6967002B2 (ja) * 2015-12-15 2021-11-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トランスグルタミナーゼ認識部位を有するｆｋｂｐドメイン
US12436148B2 (en) * 2018-07-02 2025-10-07 Siemens Healthcare Diagnostics Inc. Direct immunoassay measurement of autoantibodies
DE102019004812B4 (de) 2019-07-10 2021-03-18 Institut Virion-Serion GmbH Würzburg Rubella Virus Spike Konstrukt
CN115197941A (zh) * 2021-04-08 2022-10-18 中国科学院分子细胞科学卓越创新中心 具有分子伴侣功能的rna及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501093A (ja) 1996-09-26 2001-01-30 メディカル リサーチ カウンシル シャペロン断片
HK1048138B (zh) * 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
MXPA03011455A (es) 2001-06-22 2004-04-05 Hoffmann La Roche Complejo soluble que comprende glucoproteina de superficie retroviral.
US7604935B2 (en) * 2005-10-26 2009-10-20 Roche Diagnostics Operations, Inc. Soluble rubella E1 envelope protein variants
EP1780282B1 (en) * 2005-10-26 2010-12-08 Roche Diagnostics GmbH Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies

Also Published As

Publication number Publication date
CA2705716A1 (en) 2009-06-18
ES2450998T3 (es) 2014-03-26
WO2009074318A2 (en) 2009-06-18
CN101939330A (zh) 2011-01-05
HK1148026A1 (en) 2011-08-26
US8551696B2 (en) 2013-10-08
EP2222694A2 (en) 2010-09-01
JP2011505811A (ja) 2011-03-03
CN101939330B (zh) 2014-06-04
EP2222694B1 (en) 2014-01-15
CA2705716C (en) 2013-03-19
WO2009074318A3 (en) 2009-07-30
US20110059552A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
JP5461423B2 (ja) 新規風疹ｅ１エンベロープタンパク質変異体および抗風疹抗体の検出におけるその使用
CN104080801B (zh) 可溶的免疫反应性的苍白密螺旋体TpN47抗原
US11567079B2 (en) Soluble and immunoreactive variants of HTLV capsid antigen P24
CN110996986B (zh) Hcv抗原的多表位融合蛋白及其用途
EP1780282B1 (en) Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies
JP4116054B2 (ja) シャペロン融合タンパク質としての風疹ｅ１エンベロープタンパク質変異体の組換え発現、可溶性で天然様かつ免疫反応性の抗原コンホメーションへのそのリフォールディングならびに抗風疹抗体の検出におけるその用途
CN115843334B (zh) 用于抗体免疫测定的冠状核衣壳抗原
HK1148026B (en) Novel rubella e1 envelope protein variants and their use in the detection of antirubella antibodies
HK1202126B (en) Soluble immunoreactive treponema pallidum tpn47 antigens
CN106699895A (zh) 一种新型融合抗原和包含其的检测试剂盒及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130802

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140115

R150 Certificate of patent or registration of utility model

Ref document number: 5461423

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250